DPPA(EPI) LNPs enhanced tumor accumulation by 18.4-fold compared to free drug.
DPPA(EPI) LNPs demonstrated a sustained-release effect and high stability.
In vivo studies showed a significant reduction in tumor cell proliferation by 55% and a 60% decrease in vascular density.
The combination of DPPA(EPI) LNPs with a PD-1 inhibitor improved anti-tumor immunity activation in the tumor environment.
These results suggest that modulating the could enhance the efficacy of immune checkpoint inhibitors.
AI simplified
BACKGROUND: Immune checkpoint inhibitor (ICI) therapies have marked a significant breakthrough in tumor immunotherapy. However, their clinical efficacy remains suboptimal in many cases. Emerging evidence indicates that resistance to ICIs is largely driven by the immunosuppressive nature of the (TME). Modulating the TME-through conventional chemotherapy or anti-angiogenic therapies has been shown to enhance immune activation and improve the therapeutic response to ICIs.
METHODS: In this study, we developed epirubicin (EPI)-loaded lipid nanoparticles, termed DPPA(EPI) LNPs, which integrate the chemotherapeutic agent EPI with the anti-angiogenic lipid DPPA, enabling co-delivery and targeted enrichment within tumors. The cytotoxicity and anti-vascular endothelial cell tube formation properties of DPPA(EPI) LNPs were tested in vitro. The biosafety, anti-tumor ability and immunoactivities were tested on orthotopic tumor models of both breast cancer and hepatoma in vivo.
RESULTS: DPPA(EPI) LNPs showed the advantages of uniformed particle size, high stability, good sustained-release effect. Compared to free drug, DPPA(EPI) LNPs significantly prolonged blood circulation (21.7% remaining at 12 h vs.16.5% at 30 min for free drug), enhanced tumor accumulation (18.4-fold change than free drug) and had well biological safety. In vivo, DPPA (EPI) LNPs showed excellent anti-tumor therapeutic efficacy by significantly inhibiting tumor cell proliferation (Ki67â cells reduced by 55%), reducing tumor angiogenesis (vascular density by 60%), and inducing stronger effect both in 4T1 orthotopic tumor model and Hepa1-6 orthotopic tumor model. And the treatment of DPPA (EPI) LNPs combined with programmed cell death protein 1 (PD-1) inhibitor further improved the activation of anti-tumor immunity in the TME, which leads to more significant inhibition of the tumor growth.
CONCLUSION: This dual-function nanoplatform-combining chemotherapy and anti-angiogenic therapy-substantially improved the efficacy of PD-1 blockade in both breast cancer and hepatocellular carcinoma (HCC) models. These findings offer a promising strategy and experimental foundation for TME modulation and the advancement of combination immunotherapy.
Key numbers
21.7%
Increase in Blood Circulation Time
Remaining drug percentage at 12 hours post-administration.
55%
Decrease in Tumor Cell Proliferation
Reduction in + cells in treated tumors.
60%
Decrease in Vascular Density
Reduction in + vessels in treated tumors.
Full Text
We canât show the full text here under this license. Use the link below to read it at the source.
